Abstract: The present invention relates to bispecific and other multispecific antigen binding constructs. In certain aspects, the invention relates to bispecific antigen binding constructs comprising a single domain antibody (VHH) antigen binding region fused to an IgG Fc domain; a heavy chain-Fc domain portion of a conventional IgG antibody, and a light chain portion of a conventional IgG antibody. The bispecific antigen binding constructs of the invention are capable of targeting two different antigens separately or in a protein complex.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the cytokine receptor IL-22R, particularly human IL-22R. The invention also relates to pharmaceutical compositions comprising said antibodies or antigen binding fragments thereof, and methods of treating psoriasis, psoriatic arthritis or atopic dermatitis.

Abstract: The present invention relates to a protein binding to GARP in the presence of TGF-ß and uses thereof.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Abstract: The present invention relates to antibodies and antigen binding fragments thereof derived from antibodies raised by DNA immunization of host animals, particularly camelids (e.g. llama). The antibodies and antigen binding fragments thereof bind to proteins which may be particularly large in size (at least 1115 amino acids in length), or have at least 8 transmembrane domains, or are naturally encoded by nucleotide sequences which are difficult to replicate in standard or common E. coli strains. The present invention also relates to antibodies and antigen binding fragments thereof which bind to ion channels, in particular the voltage-gated sodium channel Nav1.7. Methods of raising antibodies against particular protein targets by a process of DNA immunization are also provided.

Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).